Haplotypic structure of abcb1/mdr1 gene modifies the risk of the acute allograft rejection in renal transplant recipients

Transplantation

Volumn 86, Issue 9, 2008, Pages 1206-1213

  Bandur, Stepan ^a   Petrasek, Jan ^a   Hribova, Petra ^a   Novotna, Eva ^a   Brabcova, Irena ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Cyclosporine; Cytochrome P450; Haplotypes; P glycoprotein; Pharmacogenetics; Renal transplantation; Single nucleotide polymorphism; Tacrolimus

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HLA DR ANTIGEN; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; ABCB1 PROTEIN, HUMAN; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANAMNESIS; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED GRAFT FUNCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; GENE LOCUS; GENE STRUCTURE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOTYPE; HOMOZYGOSITY; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION STUDY; ALLELE; ALLOTRANSPLANTATION; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; GENETICS; GRAFT REJECTION; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 58149148271     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318187c4d1     Document Type: Article

References (43)

1. Kyhl LE, Rasmussen SN, Aarons L, et al. Population pharmacokinetics of cyclosporine: Influence of covariables and assessment of cyclospor-ine absorption in kidney, lung, heart and heart+lung transplanted patients. Transplant Proc 1998; 30: 1680.
2. Venkatamaranan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
3. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant 2002; 2: 789.
4. Staatz C, Taylor P, Tett S. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905.
5. HoncharikN, YatscoffRW, JefferyJR, etal. The effect of meal composition on cyclosporine absorption. Transplantation 1991; 52: 1087.
6. Tang C, Lin JH, Lu AY. Metabolism- based drug- drug interactions: Wshat determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005; 33: 603.
7. Dunn CJ, Waqstaff AJ, Perry CM, et al. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation. Drugs 2001; 61: 1957.
8. Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 2005; 5: 207.
9. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487.
10. McMillan MA. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 1989; 42: 135.
11. Vincent SH, Karanam BV, Painter SK, et al. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as a major enzymes responsible for its metabolism. Arch Biochem Biophhys 1992; 294: 454.
12. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 2006; 112: 457.
13. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: Cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315.
14. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473.
15. Amirimani B, Ning B, Deitz AC, et al. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42: 299.
16. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
17. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525.
18. Haufroid V, Mourad M, van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
19. Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
20. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977.
21. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacoge-netics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 843.
22. MacPhee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmaco-genetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499.
23. Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380.
24. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 2006; 82: 1677.
25. Masuda S, Goto M, Fukatsu S, et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin Pharmacol Ther 2006; 79: 90.
26. Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705.
27. Mai I, Perloff ES, Bauer S, et al. MDR1 haplotypes derived from exons 21 and26 donot affect the steady-state pharmacokinetics oftacrolimus in renal transplant patients. Br J Clin Pharmacol 2004; 58: 548.
28. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366: 1315.
29. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
30. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169.
31. The International HapMap Project. Nature 2003; 426: 789.
32. Excoffier L, Laval G, Schneider S. Arlequin ver. 3.0: An integrated software package for population genetics data analysis. Evol Bioinform Online 2005; 1: 47.
33. Slatkin M, Excoffier L. Testing for linkage disequilibrium in genotypic data using the Expectation-Maximization algorithm. Heredity 1996; 76 (Pt 4): 377.
34. Anglicheau D, Verstuyft C, Laurent- Puiq P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1955.
35. Wasmuth HE, Matern S, Lammert F. From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than two. Hepatology 2004; 39: 604.
36. Hull J, Rowlands K, Lockhart E, et al. Haplotype mapping of the bron-chiolitis susceptibility locus near IL8. Hum Genet 2004; 114: 272.
37. Fredericks S, Jorga A, MacPhee IA, et al. Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. Clin Transplant 2007; 21: 252.
38. Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422.
39. Hollox EJ, PoulterM, Zvarik M, et al. Lactase haplotype diversityinthe Old World. Am J Hum Genet 2001; 68: 160.
40. Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001; 27: 134.
41. Eng HS, Mohamed Z, Calne R, et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69: 1858.
42. Kirkwood BJS. Essential medical statistics [ed. 2]. Boston, Blackwell Science 2003, p 426.
43. Ioannidis JP, Trikalinis TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006; 167: 609.